LifeCodexx AG

What LifeCodexx AG does

LifeCodexx AG (legally operating as Eurofins LifeCodexx GmbH since its 2018 acquisition by Eurofins Scientific) is a Germany-based clinical diagnostics laboratory founded in 2010 and headquartered in Planegg near Munich, with testing operations in Konstanz. The company's single core product is PraenaTest® (also marketed internationally as PrenaTest®), a non-invasive prenatal test (NIPT) launched in 2012 as Europe's first commercial NIPT. The test analyzes cell-free fetal DNA (cfDNA) extracted from maternal blood to screen for chromosomal disorders including trisomies 21, 18, and 13, sex chromosome aneuploidies, rare autosomal aneuploidies (added 2019), copy number variations ≥7 Mb, and the 22q11.2 microdeletion (DiGeorge syndrome). Testing is performed in certified German laboratories under the German Genetic Diagnostics Act (GenDG) and strict European data protection standards, with results delivered to ordering physicians.

The business model is a B2B diagnostic laboratory service. Gynecologists and medical practices order PraenaTest blood collection kits through an exclusive online ordering portal; samples are drawn at the practice and shipped to the German laboratory for analysis. Pricing is transaction-based, with self-pay tests starting at €169 and a GOÄ-based price of €214.50. Since July 2022, the trisomy 21/18/13 panel is covered by German statutory health insurance (GKV) for many indications, materially expanding the insured addressable market. Marketing is concentrated on healthcare professionals via scientific congresses, dedicated NIPT expert and service hotlines, a multilingual website (German, English, Turkish, Russian), and field sales. The company operates as a wholly-owned subsidiary of Eurofins Scientific, and as of 2024 the Praena portfolio and tasks have been transferred to Eurofins Humangenetik und Pränatal-Medizin MVZ GmbH, indicating intra-group consolidation of prenatal diagnostics within the parent.

The product portfolio is intentionally narrow: PraenaTest®/PrenaTest® is the sole product offering, and the company's commercial position relies on first-mover brand recognition (Europe's first NIPT, 2012), clinically validated performance (>99% accuracy, 0.1% false-positive rate), and physician relationships built over 12+ years. Geographic reach spans Europe, Middle East, and Asia. No API, mobile application, or developer-facing integration is offered, and no AI/ML capabilities are disclosed. The company is led by Managing Directors Dr. Florian Vogel and Maja Herberg.

Name

LifeCodexx AG

Legal name

Eurofins LifeCodexx GmbH

Website

https://lifecodexx.com

Company type

Private

Founded year

2010

Operating status

Operating

Short description

LifeCodexx AG (Eurofins LifeCodexx GmbH) operates a certified German NIPT laboratory offering PraenaTest®, Europe's first commercial non-invasive prenatal test, serving gynecological practices and pregnant women across Europe, the Middle East, and Asia since 2012.

Ownership category

akta.pro rank

Product category

Prenatal Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Maternal-Fetal Medicine (High-Risk Pregnancy/Perinatology) (HLAKAJAB)

Keywords

• Non-invasive prenatal testing
• Cell-free DNA analysis
• Prenatal diagnostics
• Chromosomal disorder screening
• Genetic testing services

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Services: NIPT testing services provided to pregnant women through gynecological practices. Revenue generated through insurance billing (GKV coverage since July 2022 for trisomies 21, 18, 13) or self-pay patients. Test processing in certified German laboratories.
2. Blood Collection Kit Sales: Sale of PraenaTest blood collection kits to medical practices and clinics. Practices order through online ordering portal.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

LifeCodexx AG operates a specialized diagnostic laboratory that performs non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) extracted from maternal blood. The company's flagship offering, PraenaTest/PrenaTest, screens for fetal chromosomal abnormalities including trisomies 21, 18, and 13. Services are delivered to gynecological practices, which in turn offer the test to pregnant women as part of routine prenatal care.

Product overview

LifeCodexx AG offers a focused product portfolio centered on the PraenaTest® (also branded internationally as PrenaTest®), a non-invasive prenatal test (NIPT). This single core product analyzes cell-free fetal DNA (cfDNA) from maternal blood to screen for chromosomal disorders. The test is ordered by physicians, performed in German-certified laboratories, and results are delivered to doctors who communicate them to patients. No modular add-ons, platform extensions, or separate service modules are offered—the company operates as a diagnostic laboratory service provider with the PraenaTest/PrenaTest as its sole product offering.

Differentiator

Problem solved

Functional benefit

Brands

• PraenaTest: Non-invasive prenatal test (NIPT) for detecting chromosomal disorders in unborn children from maternal blood, including trisomies 21, 18, 13, sex chromosome aneuploidies, rare autosomal aneuploidies (RAA), CNVs, and 22q11.2 microdeletion.

Products and services

• PraenaTest / PrenaTest (Non-Invasive Prenatal Test) Laboratory diagnostic service that analyzes cell-free fetal DNA from a maternal blood sample to screen for fetal chromosomal disorders, primarily trisomies 21, 18, and 13. Marketed as PraenaTest in Germany and PrenaTest for international/English-language markets. The service is ordered by gynecologists and genetic counselors on behalf of pregnant women, typically from the 10th week of gestation onward.

Quantifiable outcome

• Test accuracy >99% depending on chromosomal disorder tested
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves5 records

Expansion highlights2 records

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Customer concentration

• Xx.com/LifeCodexx
• LinkedInlinkedin.com/company/lifecodexx-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeCodexx AG